Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Intravitreal bevacizumab in choroidal neovascularization associated with Best's vitelliform dystrophy.

Mandal S, Sinha S, Venkatesh P, Vashisht N.

Indian J Ophthalmol. 2011 May-Jun;59(3):262-3. doi: 10.4103/0301-4738.81034. No abstract available.

2.

Intravitreal bevacizumab for choroidal neovascular membrane associated with Best's vitelliform dystrophy.

Rishi E, Rishi P, Mahajan S.

Indian J Ophthalmol. 2010 Mar-Apr;58(2):160-2. doi: 10.4103/0301-4738.60096.

3.

Phenotypic variability due to a novel Glu292Lys variation in exon 8 of the BEST1 gene causing best macular dystrophy.

Sohn EH, Francis PJ, Duncan JL, Weleber RG, Saperstein DA, Farrell DF, Stone EM.

Arch Ophthalmol. 2009 Jul;127(7):913-20. doi: 10.1001/archophthalmol.2009.148.

4.

New VMD2 gene mutations identified in patients affected by Best vitelliform macular dystrophy.

Marchant D, Yu K, Bigot K, Roche O, Germain A, Bonneau D, Drouin-Garraud V, Schorderet DF, Munier F, Schmidt D, Le Neindre P, Marsac C, Menasche M, Dufier JL, Fischmeister R, Hartzell C, Abitbol M.

J Med Genet. 2007 Mar;44(3):e70. Epub 2007 Feb 7.

6.

An unusual presentation of Best's disease.

Fletcher RC, Jampol LM, Rimm W.

Br J Ophthalmol. 1977 Nov;61(11):719-21.

7.

Pseudoinflammatory macular dystrophy.

Carr RE, Noble KG.

Trans Am Ophthalmol Soc. 1977;75:255-71.

Supplemental Content

Support Center